Interactions on record — worth a quick check against your medications. Check your meds →
Dietary supplement

Vinpo-15 Ingredients & Drug Interactions

by AOR Advanced Orthomolecular Research Premium

Capsule Category: Non-nutrient/non-botanical
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

Vinpo-15 is a dietary supplement by AOR Advanced Orthomolecular Research Premium with 1 active ingredient. Its ingredients are commonly taken for memory and cognitive support, brain blood flow, stroke recovery.Based on those ingredients, 208 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are Vinpocetine. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of Vinpo-15 by AOR Advanced Orthomolecular Research Premium

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Full disclosure
Ingredient Transparency · database check
Full

Every active ingredient lists its own amount on the label.

Why this rating?
  • The label discloses an exact amount for 1 of its 1 active ingredient.
  • No proprietary blends here — you can verify the dose of every single component.

Vinpo-15 contains one active ingredient: vinpocetine, a compound believed to support blood flow and oxygen delivery to the brain. The capsule also contains inactive ingredients — microcrystalline cellulose and sodium stearyl fumarate — which are standard fillers and flow agents.

Does it work?

Moderate evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Moderate

Some clinical evidence supports this product's ingredients for its stated purpose, but it isn't conclusive.

Why this rating?
  • The label markets this product for: memory and cognitive support with brain blood flow.
  • We looked for evidence on: Age-related cognitive decline, Memory, Stroke, Tinnitus, Hearing loss, Dementia — and 3 related terms.
  • The strongest evidence on file: Vinpocetine is rated "Possibly Effective" for Dementia (Natural Medicines).
  • Also on file: Vinpocetine is rated "Insufficient Reliable Evidence To Rate" for Age-related cognitive decline, Hearing loss, Memory, Stroke, and more.

The evidence for vinpocetine is mixed. It's rated possibly effective for dementia, meaning some research supports its use but the evidence isn't conclusive.

For tinnitus, motion sickness, stroke recovery, and chronic fatigue syndrome, there isn't enough reliable evidence to rate how well it works. Talk with your pharmacist about whether the research matches what you're hoping it'll do for you.

The evidence, ingredient by ingredient Vinpocetine

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 1 of the 1 matched ingredient.
  • Pregnancy & breastfeeding safety ratings cover 1 of 1.
  • General safety write-ups exist for 1 of 1.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Short-term, vinpocetine is generally well tolerated. The most common side effects from oral use are anxiety, dizziness, headache, flushing, stomach discomfort, sleep problems, and hives.

Rare but serious side effects include abnormally low white blood cell counts, irregular heartbeat, and seizures. The FDA advises against vinpocetine in pregnancy — don't use it if you're pregnant or could become pregnant.

There isn't enough safety data for breastfeeding either, so it's best avoided then. Long-term safety hasn't been well studied.

Side effects, ingredient by ingredient Vinpocetine

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 1 of the 1 matched ingredient can interact with medications — Vinpocetine.
  • The most serious interaction on file is rated Moderate.
  • Some involve high-stakes drug classes: anticoagulant / antiplatelet drugs.
  • For scale: 208 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Before taking Vinpo-15, double-check if you're on any blood thinners or antiplatelet medications — vinpocetine can increase bleeding risk with these drugs. If you take warfarin (Coumadin), the risk is lower but still present.

Also check any drugs metabolized by the CYP2C9 liver enzyme, as vinpocetine might raise their levels, though this hasn't been confirmed in people.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFully disclosed formula with some supporting evidence for its stated purpose. Moderate medication interactions have been identified, and safety information is well characterized.

Vinpo-15 may be worth considering if you're interested in cognitive support and have discussed it with your doctor. If you take any blood thinners, antiplatelet drugs (like aspirin), or medications processed through the liver, check them against the tool on this page first.

Pregnant people and those breastfeeding should skip it. Talk to your pharmacist before you start.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 1 of 1 active ingredient matched to our full ingredient reviews (monographs). Based on the product label dated Mar 24, 2020.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Vinpo-15, straight from the product label.

Brand AOR Advanced Orthomolecular Research Premium
Barcode (UPC) 624917080285
Net contents 90 Vegetarian Capsule(s)
Market status On market
Date entered into DSLD Mar 24, 2020
DSLD ID 214742
Product type Non-nutrient/non-botanical
Supplement form Capsule
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Vegan, Vegetarian, Adult (18 - 50 Years), Women (not pregnant or lactating), Gluten Free, Dairy Free
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Vinpo-15 by AOR Advanced Orthomolecular Research Premium, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
1 Capsule(s)
Maximum serving Sizes:
1 Capsule(s)
Servings per container
90
UPC/BARCODE
624917080285
IngredientAmount% DV
Vinpocetine45 mg--

Other ingredients: Capsule, Microcrystalline Cellulose, Sodium Stearyl Fumarate

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Formulation

GMP Manufacturing Quality assured Independent testing

Supports optimal brain function

Vegan

Non-GMO Gluten free

AOR guarantees that all ingredients have been declared on the label.

Made without wheat, gluten, corn, nuts, peanuts, sesame seeds, sulfites, mustard, soy, dairy, eggs, fish, shellfish or any animal byproduct.

Precautions

Do not use if safety seal is broken

Warning: Do not take if you are pregnant or lactating, have a medical condition (high or low blood pressure, cardiac arrhythmia, dementia, or have suffered a stroke), or if you’re taking any medication (blood thinners).

Keep out of reach of children.

Caution: Hypersensitivity is known to occur, and some people may experience anxiety, gastrointestinal discomfort, dizziness or headaches, in which case, discontinue use.

To report a serious adverse event or obtain product information, call 1-866-215-0450

Storage

Store tightly sealed in a cool, dry place

Formula

Discussion: Vinpo-15 is vinpocetine, a compound found in voacanga. Studies show that vinpocetine has similar benefits to Ginkgo biloba.

Suggested/Recommended/Usage/Directions

Directions: Take 1 capsules 1-3 times a day with food, or as directed by a qualified health care practitioner.

FDA Disclaimer Statement

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

FDA Statement of Identity

Dietary Supplement

General Statements

Product of Canada

See for yourself

Vinpo-15 by AOR Advanced Orthomolecular Research Premium label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in Vinpo-15 by AOR Advanced Orthomolecular Research Premium

This is the 1 active ingredient this product is made of. Select it to open its full monograph.

Serving size1 Capsule(s) Dosage formCapsule Servings per container90 Amounts shown are per serving.

Vinpocetine

Interacts with
208 drugs
45 mg per serving Form: Voacanga africana

Vinpocetine is a lab-made compound based on a chemical from the periwinkle plant, and it is marketed mainly for memory and brain health. The evidence...

Vinpocetine monograph & interactions

Other (inactive) ingredients: Capsule, Microcrystalline Cellulose, Sodium Stearyl Fumarate. These complete the product’s ingredient list but are not active constituents.

Interaction report

Vinpo-15 by AOR Advanced Orthomolecular Research Premium Drug Interactions

Want to check YOUR meds against Vinpo-15?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
208Drugs
208 Moderate

Ingredients driving the most interactions

Each ingredient & the kinds of drugs it affects

For each ingredient in Vinpo-15 with known interactions, here are the types of medications it can affect. Open any type for the detail — or search your exact drug in the checker above.

Vinpocetine3 drug types · 208 drugs

Anticoagulant/Antiplatelet Drugs

Vinpocetine might increase the risk of bleeding when taken with anticoagulant or antiplatelet drugs.
Clinical research shows that vinpocetine decreases red blood cell aggregation, as well as plasma and whole blood viscosity. This effect has been seen with intravenous vinpocetine 1 mg/kg and oral vinpocetine 30 mg daily. Vinpocetine also seems to have antiplatelet effects.

Likelihood Possible Evidence B
Cytochrome P450 2C9 (Cyp2C9) Substrates

Theoretically, vinpocetine might increase levels of drugs metabolized by CYP2C9.
In vitro research shows that vinpocetine weakly inhibits CYP2C9. However, this effect has not been reported in humans.

Likelihood Possible Evidence D
Warfarin (Coumadin)

Vinpocetine might modestly increase the risk of bleeding when taken with warfarin.
Clinical research shows that the combination of warfarin and vinpocetine leads to slight increases in prothrombin time and the area under the concentration curve for warfarin. However, these increases were small, and researchers suggest that this interaction is not likely to be clinically significant in most patients.

Likelihood Possible Evidence B
The maker

Brand information

Manufacturer and brand details for Vinpo-15, from the product label.

AOR Advanced Orthomolecular Research Premium

See all AOR Advanced Orthomolecular Research Premium products
Name
AOR Inc.
Street Address
30 Industrial West
City
Clifton
State
NJ
ZipCode
07012
Phone Number
1-866-215-0450
Pharmacist Counseling Corner

Vinpo-15 by AOR Advanced Orthomolecular Research Premium: Common Questions

Does Vinpo-15 by AOR Advanced Orthomolecular Research Premium interact with any medications?
Yes. Based on its ingredients, Vinpo-15 has a known interaction with 208 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Vinpo-15 contains a single active ingredient, and that one ingredient can interact with many different medications on its own. We check it against each medication and show the mechanism responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Is vinpocetine safe in pregnancy?
No. The FDA has warned that pregnant people and those who could become pregnant should not use vinpocetine. If you're pregnant or planning pregnancy, avoid this product.
Can I take this while breastfeeding?
There isn't enough safety information to recommend it while breastfeeding. It's best to avoid it during that time.
What are the most common side effects?
Anxiety, dizziness, headache, flushing, stomach discomfort, sleep problems, and hives have been reported with oral vinpocetine. Most people tolerate it well short-term, but long-term safety hasn't been established.
Does vinpocetine actually work for dementia or brain fog?
For dementia, the evidence is possibly effective — meaning some research supports it, but it's not definitive. For other conditions like tinnitus or fatigue, there isn't enough reliable evidence to say how well it works.
Why is there a warning about blood thinners?
Vinpocetine thins the blood slightly and reduces how red blood cells stick together. Combined with blood thinners or aspirin-type drugs, this raises your bleeding risk — so these combinations need careful monitoring by your pharmacist or doctor.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Vinpo-15 is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Vinpo-15 label
Sources

Sources & How We Checked

Vinpo-15's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 27 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Vinpocetine 27 references
  1. Hindmarch I, Fuchs HH, Erzigkeit H. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol 1991;6:31-43. PubMed
  2. Balestreri R, Fontana L, Astengo F. A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J Am Geriatr Soc 1987;35:425-30. PubMed
  3. Akopov SE, Gabrielian ES. Effects of aspirin, dipyridamole, nifedipine and cavinton which act on platelet aggregation induced by different aggregating agents alone and in combination. Eur J Clin Pharmacol 1992;42:257-9. PubMed
  4. Kidd PM. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. Altern Med Rev 1999;4:144-61..
  5. Wollschlaeger B. Efficacy of vinpocetine in the management of cognitive impairment and memory loss. JANA 2001;4:25-30.
  6. Hitzenberger G, Sommer W, Grandt R. Influence of vinpocetine on warfarin-induced inhibition of coagulation. Int J Clin Pharmacol Ther Toxicol 1990;28:323-8..
  7. Dekoninck, W. J., Jocquet, P., Jacquy, J., and Henriet, M. Comparative study of the clinical effects of vincamine + glycerol versus glycerol + placebo in the acute phase of stroke. Arzneimittelforschung. 1978;28(9):1654-1657.
  8. Fischhof, P. K., Moslinger-Gehmayr, R., Herrmann, W. M., Friedmann, A., and Russmann, D. L. Therapeutic efficacy of vincamine in dementia. Neuropsychobiology 1996;34(1):29-35. PubMed
  9. Feher, G., Koltai, K., Kesmarky, G., Horvath, B., Toth, K., Komoly, S., and Szapary, L. Effect of parenteral or oral vinpocetine on the hemorheological parameters of patients with chronic cerebrovascular diseases. Phytomedicine. 2009;16(2-3):111-117. PubMed
  10. Kuzuya, F. Effects of vinpocetine on platelet aggregability and erythrocyte deformability. Ther Hung. 1985;33(1):22-34.
  11. Kovacs, L. Cavinton in the treatment of acute stroke. Ther Hung. 1985;33(1):50-57.
  12. Osawa, M. and Maruyama, S. Effects of TCV-3B (vinpocetine) on blood viscosity in ischemic cerebrovascular diseases. Ther.Hung. 1985;33(1):7-12.
  13. Ebi, O. Open-labeled phase III clinical trials with vinpocetine in Japan. Ther.Hung. 1985;33(1):41-49.
  14. Richichi, I., Valsecchi, O., Falcone, C., Sofi, A., and Zanini, L. [A case of "torsade de pointe" during vincamine therapy]. Minerva Cardioangiol. 1978;26(3):197-200.
  15. Dany, F., Merle, L., Goudoud, J. C., Liozon, F., Blanc, P., Bouvot, J. C., Nicot, G., and Dangoumau, J. [Cardiac toxicity of vincamine: a seven cases report of ventricular arrhythmias by parenteral administration of vincamine (author's transl)]. Therapie
  16. Fenzl, E., Apecechea, M., Schaltenbr, R., and Fridel, R. Long term study concerning tolerance and efficacy of vinpocetine in elderly patients suffering from a mild to moderate organic psychosyndrome. Senile dementia: early detection 1986;580-585.
  17. Peruzza, M. and DeJacobis, M. A double-blind placebo controlled evaluation of the efficacy and safety of vinpocetine in the treatment of patients with chronic vascular or degenerative senile cerebral dysfunction. ADV THER 1986;3(4):201-209.
  18. Manconi, E., Binaghi, F., and Pitzus, F. A double-blind clinical trial of vinpocetine in the treatment of cerebral insufficiency of vascular and degenerative origin. CURR THER RES, CLIN EXP 1986;40(4):702-709.
  19. Blaha, L., Erzigkeit, H. L., Adamczyk, L. A., Freytag, L. S., and Schaltenbrand, R. Clinical evidence of the effectiveness of vinpocetine in the treatment of organic psychosyndrome. Human Psychopharmacology: Clinical & Experimental 1989;4(2):103-111. DOI
  20. Shimizu, Y., Saitoh, K., Nakayama, M., Suto, K., Daikohara, R., and Nemoto, T. Agranulocytosis induced by vinpocetine. Medicine On-line 2011;
  21. Kong L, Song C, Ye L, et al. The Effect of Vinpocetine on Human Cytochrome P450 Isoenzymes by Using a Cocktail Method. Evid Based Complement Alternat Med. 2016;2016:5017135. PubMed
  22. Vinpocetine in Dietary Supplements. FDA Food/Dietary Supplements/Products & Ingredients. Available at: http://www.fda.gov/Food/DietarySupplements/ProductsIngredients/ucm518478.htm. Accessed 6 September 2016.
  23. Statement on warning for women of childbearing age about possible safety risks of dietary supplements containing vinpocetine. FDA Food/Dietary Supplements/Products & Ingredients. Available at: https://www.fda.gov/news-events/press-announcements/statement-
  24. Zhang W, Huang Y, Li Y, et al. Efficacy and safety of vinpocetine as part of treatment for acute cerebral infarction: A randomized, open-label, controlled, multicenter CAVIN (Chinese Assessment for Vinpocetine in Neurology) trial. Clin Drug Investig 2016; PubMed
  25. National Toxicology Program. NTP technical report on the prenatal development toxicity studies of vinpocetine (CAS No. 42971-09-5) in Sprague Dawley Rats and New Zealand White Rabbits (Gavage Studies). Research Triangle Park, NC: National Toxicology Progr
  26. Gutiérrez-Farfán I, Reyes-Legorreta C, Solís-Olguín M, Alatorre-Miguel E, Verduzco-Mendoza A, Durand-Rivera A. Evaluation of vinpocetine as a therapy in patients with sensorineural hearing loss: a phase II, open-label, single-center study. J Pharmacol Sci PubMed
  27. Hu X, Guo K, Li J, et al. Postoperative ecchymoma of eyelid after botulinum toxin injection for hemifacial spasm: a case report. Front Neurol 2023;14:1171303. PubMed

See these in context on the Vinpocetine monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring